KCNK3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL221421	0.56	20/20
SCHEMBL259666	0.87	11/20
Butane (SCHEMBL498343)	0.61	11/20
SCHEMBL13234	0.60	11/20
SCHEMBL183240	0.55	11/20
SCHEMBL76595	0.50	10/20
SCHEMBL259468	0.87	9/20
SCHEMBL259371	0.63	8/20
SCHEMBL259311	0.60	8/20
SCHEMBL259706	0.72	7/20
SCHEMBL113971	0.66	7/20
Flutolanil (SCHEMBL18555)	0.65	7/20
SCHEMBL259705	0.60	7/20
SCHEMBL8208	0.57	7/20
SCHEMBL528261	0.54	7/20
SCHEMBL498597	1.00	6/20
SCHEMBL498598	1.00	6/20
SCHEMBL259421	0.86	6/20
SCHEMBL394748	0.76	6/20
SCHEMBL396708	0.57	6/20

Clinical trials — most relevant to KCNK3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery	PHASE4	RECRUITING
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation	PHASE4	RECRUITING
Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation	PHASE3	COMPLETED
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	PHASE2	COMPLETED
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss	PHASE2	COMPLETED
Sandostatine® LP and Hyperinsulinism	PHASE2	COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK	PHASE1	COMPLETED
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet	PHASE1	NOT_YET_RECRUITING
Peripheral KV7 Activation for Pain Relief	EARLY_PHASE1	COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)	nan	UNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism	nan	COMPLETED
A Positional Cloning Study on Schizophrenia	nan	COMPLETED
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy	nan	UNKNOWN
Characteristics of Andersen-Tawil Syndrome	nan	COMPLETED
Na+ Channel mRNA Regulation in Heart Failure	nan	COMPLETED
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Targeting Potassium Channels to Reprogram Glioblastoma Microenvironment: in Vitro and in Vivo Studies	nan	UNKNOWN
Interaction of Potassium and Genetic Risk Variants on Diabetes Risk	nan	COMPLETED
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	nan	UNKNOWN
A Multicenter, Prospective, Non-interventional Cohort Study to Evaluate the Safety and Treatment Pattern of Sodium Zirconium Cyclosilicate for Hyperkalaemia Management in Real World Practice in China	nan	COMPLETED
The Genetic Basis of Atrial Fibrillation (AF)	nan	COMPLETED
Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome	nan	RECRUITING
Specificities of Atypical Non AutoImmune Diabetes (ANAID) in the French West Indies	nan	NOT_YET_RECRUITING
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a KCNK3 binder may also engage these)

Protein	Name	Similarity
Q3LS21	—	1.000	Q3LS21 →
O35111	—	1.000	O35111 →
Q9JL58	—	0.999	Q9JL58 →
KCNK9	Potassium channel subfamily K member 9	0.999	landscape →
Q9ES08	—	0.998	Q9ES08 →
O17185	—	0.996	O17185 →
P34410	—	0.995	P34410 →
O54912	—	0.994	O54912 →
Q622X0	—	0.993	Q622X0 →
KCNK10	Potassium channel subfamily K member 10	0.992	landscape →
Q63ZI0	—	0.992	Q63ZI0 →
Q8BUW1	—	0.991	Q8BUW1 →
Q22271	—	0.990	Q22271 →
Q920B6	—	0.990	Q920B6 →
Q9W3D3	—	0.988	Q9W3D3 →
Q9JIS4	—	0.987	Q9JIS4 →
O60353	—	0.987	O60353 →
Q9VR07	—	0.987	Q9VR07 →
Q5UE96	—	0.987	Q5UE96 →
P97438	—	0.987	P97438 →
P0C550	—	0.987	P0C550 →
A0A125YWU9	—	0.986	A0A125YWU9 →
Q8WMU5	—	0.986	Q8WMU5 →
P98999	—	0.986	P98999 →
Q23435	—	0.986	Q23435 →
Q9TUI4	—	0.986	Q9TUI4 →
Q28527	—	0.986	Q28527 →
Q5RAQ1	—	0.985	Q5RAQ1 →
P34586	—	0.985	P34586 →
Q9DGG6	—	0.985	Q9DGG6 →